Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 24, 2020 • 5:15 PM EDT

Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit

March 23, 2020 • 4:30 PM EDT

Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering

March 3, 2020 • 5:00 PM EST

Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market

February 28, 2020 • 8:45 AM EST

Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)

February 26, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering

February 11, 2020 • 4:01 PM EST

Tonix Pharmaceuticals Prices $7.5 million Public Offering

February 7, 2020 • 8:45 AM EST

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

February 5, 2020 • 5:15 PM EST

Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences

February 4, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

January 29, 2020 • 4:15 PM EST

« Previous
1
2
3
4
5
6
7
8
9
10
...37
Next »

Show All

News / Press Releases : Press Releases